Guava Technologies has launched a new and enhanced version of the company's Guava RapidQuant IgG Antibody Quantification Assays for mouse and human antibodies
Faster and easier than the average enzyme-linked immunosorbent assay (ELISA), the traditional approach for antibody quantification, RapidQuant Assays help users select of optimal clones from hybridoma screens.
According to David King, vice president R+D and operations, Guava Technologies, these mix-and-read, bead-based assays were developed with users in mind.
"We wanted to give scientists an assay that almost ran itself", said King.
"The protocol is basically three simple steps; we eliminated the time-consuming sample preparation and washes common with many ELISAs".
Users are quickly adopting the assays as critical tools for antibody research.
"The RapidQuant IgG Assay expands our toolbox for differentiating monoclonal antibody cultures and is an essential tool when sub-cloning to obtain higher antibody secretors", said Dr John Kenney, president, Antibody Solutions, Mountain View, California, USA.
Results from RapidQuant Assay are read on a plate-based benchtop flow cytometer, such as the Guava EasyCyte Plus System, and are equivalent to those obtained with traditional ELISAs.
Entirely new, the assay-specific RapidQuant Software gives users easy and complete data acquisition and analysis capabilities in a single program.
Highly intuitive, it leads users directly to results while also offering customisable options for flexibility.
The assay processes are simplified with easy set-up, straightforward data acquisition, automatic analysis, and extensive data management options.
The end result is an ideal assay for hybridoma screening that combines the reliability of flow cytometry with the convenience of a microplate-based format.
